Unlike other types of cancer, which are silent and asymptomatic, ovarian cancer may produce very serious signs and symptoms even at a very early stage. Some of the most common symptoms of ovarian cancer can be very similar to less serious conditions such as urinary tract infections or mild abdominal problems. These symptoms include:
What is Ovarian Cancer?
varian cancer occurs when some cells in your ovaries start to rapidly divide uncontrollably, creating growths or tumors around the ovaries and surrounding tissues. According to the American Cancer Association, ovarian cancer is the fifth most common type of cancer among women, and it is estimated that more than 20,000 women will be diagnosed with this type of cancer every year.
Ovarian cancer affects the ovaries, which are a keypart of the female reproductive system. All females have two ovaries, each about the size of an almond, which lie on either side of the uterus and are responsible for creating and releasing eggs during the menstrual cycle, as well as producing the two mean female sex hormones: estrogen and progesterone.
How is Ovarian Cancer Diagnosed?
- Indigestion and changes in appetite
- Changes in bowel movements
- Urinary incontinence or increased urge to urinate
- Pain around the pelvis area
- Back pain
When ovarian cancer is found at its early stages, patients have nearly a 95% chance of living more than five years after their diagnosis. However, only 20% of ovarian cancer cases are found early.
Currently, there are no tests to specifically diagnose ovarian cancer. This type of cancer is usually found during routine checkups when a professional perform a pelvic exam to evaluate the shape, size and any abnormalities in around the uterus and ovaries.
Unfortunately, it is very hard to feel or see any to see or feel any tumors early, which is why most women are diagnosed later. In addition to a pelvic exam, doctors might order a transvaginal ultrasound or a CA-125 blood test.
What Causes Ovarian Cancer?
Scientists still aren’t exactly sure about what causes ovarian cancer. As with many other types of cancer, there are a number of risk factors that can increase the likelihood of a woman to develop this kind of cancer, however, have one or even a few of these risk factors doesn’t mean that a person is destined to develop the disease.
These are some risk factors that have been observed in women with ovarian cancer:
Older women seem to be more likely than younger women to develop ovarian cancer. In fact, most women with ovarian cancer have been diagnosed after menopause, and half of all ovarian cancers are diagnosed in women 60 and older.
Researchers have observed that women who continue taking hormones after menopause has ended have a higher risk of developing ovarian cancer. Additionally, women who have taken estrogen without progesterone for more than five years also have an increased risk of developing ovarian cancer.
Women with a family history of ovarian cancer (mother, sisters, grandmothers, aunts, etc.) have a higher risk of developing it than those who do not have any family history of ovarian cancer.
Having a high body mass index (BMI) has been linked to several types of cancer, including ovarian cancer. However, researchers are still trying to figure out the relationship between cancer cells and obesity.
Women who have had at least one successful pregnancy before the age of 30 seem to have a decreased risk of developing ovarian cancer, which also appears to decline with the number of children the woman has. On the other hand, women who never had children or had their first child later in life have an increased risk of developing ovarian cancer.
How is Ovarian Cancer Treated?
The treatment course for ovarian cancer depends on the stage the cancer is in. Cancer is categorized in stages in order to describe its size and severity. The stages are as follows:
Depending on which stage the ovarian cancer is found, the doctor and the patient may decide in one – or several treatments to attack cancer cells. Some common ovarian cancer treatments include:
- Hormone therapy
- Clinical trials
Ovarian Cancer Clinical Trials
Clinical trials have contributed a lot to the current survival rates of ovarian cancer. However, researchers are still trying to find better screening methods that will allow doctors to find and diagnose ovarian cancer earlier, thus improving the patient’s life expectancy. Scientists are continuously researching new, less invasive treatment options that might potentially cure ovarian cancer.
If you are interested in participating in a clinical trial, ask your doctor or contact your local hospital and/or university to find out which trials are recruiting volunteers near you.
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
on May 9, 2019 at 4:00 pm
Conditions: BRCA-Mutated Ovarian Carcinoma; BRCA1 Gene Mutation; BRCA2 Gene Mutation; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; […]
Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients
on May 1, 2019 at 4:00 pm
Conditions: Epithelial Ovarian Cancer; Anemia; Iron Deficiency AnemiaIntervention: Other: Iron SucroseSponsor: University of Wisconsin, MadisonRecruiting […]
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
on April 23, 2019 at 4:00 pm
Conditions: Fallopian Tube Cancer; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; […]
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
on March 13, 2019 at 4:00 pm
Conditions: Solid Tumor; Colon Cancer; Cholangiocarcinoma; Bladder Cancer; Ovarian Cancer; Gastric Cancer; Palpable Subcutaneous Malignant LesionsInterventions: Biological: TRK-950; Drug: Irinotecan; Drug: Leucovorin; Drug: 5-FU; Drug: Gemcitabine; […]
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
on January 9, 2019 at 5:00 pm
Conditions: Advanced Solid Tumors; Triple Negative Breast Cancer; Ovarian Cancer; Gastric Cancer; Colorectal Cancer; Glioblastoma; Biliary Tract CancersInterventions: Biological: Pembrolizumab; Drug: LenvatinibSponsors: […]
Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies
on December 4, 2018 at 5:00 pm
Conditions: Breast Cancer; Ovarian Cancer; Uterine CancerIntervention: Sponsor: National Cancer Institute (NCI)Not yet recruiting […]
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
on December 3, 2018 at 5:00 pm
Conditions: Acute Myelogenous Leukemia; Ovarian Cancer; Colorectal Cancer; Triple-negative Breast Cancer; Small-cell Lung CancerInterventions: Biological: galinpepimut-S; Drug: PembrolizumabSponsors: Sellas Life Sciences Group; […]
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
on November 20, 2018 at 5:00 pm
Conditions: Ovarian Cancer; Ovarian Carcinoma; Ovary Cancer; Endometrial Cancer; Endometrioid Adenocarcinoma; Fallopian Tube Cancer; Primary Peritoneal CarcinomaIntervention: Drug: STRO-002Sponsor: Sutro Biopharma, Inc.Recruiting […]
- Key Statistics for Ovarian Cancer. American Cancer Society (April 11, 2018). Recovered from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html